ASSERTIO THERAPEUTICS, INC. Finite-Lived Intangible Asset, Expected Amortization, Year Five
ASSERTIO THERAPEUTICS, INC. had Finite-Lived Intangible Asset, Expected Amortization, Year Five of $286.81 million as of 2019-09-30, per its 10-Q filed 2019-11-07.
Discontinued › Notes › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive · last filed 2019-11-07
- 2019-09-30: Finite-Lived Intangible Asset, Expected Amortization, Year Five $286.81M.
- 2019-06-30: Finite-Lived Intangible Asset, Expected Amortization, Year Five $286.81M.
- 2019-03-31: Finite-Lived Intangible Asset, Expected Amortization, Year Five $286.81M.
- 2018-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year Five $99.23M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year Five |
|---|---|
| 2019-09-30 | $286.81M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $286.81M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $286.81M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $99.23M 10-K · filed 2019-03-11 |
| 2018-09-30 | $99.97M 10-Q · filed 2018-11-09 |
| 2018-06-30 | $99.97M 10-Q · filed 2018-08-08 |
| 2018-03-31 | $99.97M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $99.97M 10-K · filed 2018-03-01 |
| 2017-09-30 | $102.94M 10-Q · filed 2017-11-09 |
| 2017-06-30 | $102.94M 10-Q · filed 2017-08-07 |
| 2017-03-31 | $102.94M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $102.94M 10-K · filed 2017-02-24 |
| 2016-09-30 | $108.15M 10-Q · filed 2016-11-07 |
| 2016-06-30 | $108.15M 10-Q · filed 2016-08-03 |
| 2016-03-31 | $108.15M 10-Q · filed 2016-05-06 |
| 2015-12-31 | $108.15M 10-K · filed 2016-02-26 |
| 2015-09-30 | $108.10M 10-Q · filed 2015-11-09 |
| 2015-06-30 | $108.10M 10-Q · filed 2015-08-03 |
| 2014-12-31 | $8.20M 10-K · filed 2015-02-26 |